Canadian pharmaceutical company Valeant Pharmaceuticals International Inc on Monday announced a deal to acquire US eye health company Bausch & Lomb for US$8.7 billion in cash, becoming a behemoth in the burgeoning eye care sector.
The acquisition, which had been rumored, positions Valeant to capitalize on “growing eye health trends driven by an aging patient population, an increased rate of diabetes and demand from emerging markets,” a joint statement said.
The merger also gives Valeant access to Bausch & Lomb’s large portfolio of products and “a late stage pipeline of innovative, new products.”
“With this transaction, Valeant will be a worldwide leader in both dermatology and eye health,” Valeant CEO Michael Pearson said.
Founded in 1853, privately held Bausch & Lomb, based in Rochester, New York, is best known for its contact lenses and for products related to maintaining contact lenses, such as PureVision, Optima and ReNu.
The company also manufactures eye drops for treating eye dryness, glaucoma or allergies and materials used in eye surgery.
The purchase of Bausch & Lomb by Valeant follows a series of about 15 recent acquisitions by the Canadian company over the last year totaling US$3.5 billion.
However, Bausch & Lomb is a far bigger target, enabling the Canadian firm to double its revenues in one fell swoop.
The US company, which employs 11,200 worldwide, last year reported revenues of about US$3 billion, according to a filing with US securities regulators. Valeant reported revenues of US$3.3 billion and had about 7,000 employees at the end of last year.
Both companies had losses for last year, with Bausch & Lomb reporting a loss of US$68.3 million and Valeant a loss of US$116 million. The potential Bausch & Lomb deal comes on the heels of Valeant’s reportedly unsuccessful bid to buy US pharmaceutical company Actavis for more than US$13 billion.
The transaction also replaces a plan launched in March for Bausch & Lomb to undertake an initial public offering. Valeant said the transaction would be financed with debt and approximately US$1.5 billion to US$2 billion of new equity.
Bausch & Lomb will retain its name and become a division of Valeant, while Valeant’s existing ophthalmology businesses will be integrated into the Bausch & Lomb division.
The transaction, which is expected to close in the third quarter, is subject to closing conditions and regulatory approvals.
‘BIG LOSS’: This year might see the last generation of Huawei’s Kirin chips, as their production would stop next month because they are made using US technology Chinese tech giant Huawei Technologies Co (華為) is running out of processor chips to make smartphones due to US sanctions and would be forced to stop production of its own most advanced chips, a company executive has said, in a sign of growing damage to Huawei’s business from US pressure. Huawei, one of the biggest producers of smartphones and network equipment, is at the center of US-Chinese tension over technology and security. Washington last year cut off Huawei’s access to US components and technology, and those penalties were tightened in May, when the White House barred vendors worldwide from using US
’WHITE BOX’: The open platform would give local firms access to Cisco’s cloud-based mobile network to develop 5G telecom equipment and tap into the global market The Ministry of Economic Affairs (MOEA) yesterday introduced a new 5G “open lab” in collaboration with US-based information technology and networking giant Cisco Systems Inc to address the rapidly growing “white box” 5G networking equipment market. The open lab will be a platform where Taiwanese manufacturers can access Cisco’s cloud-based mobile network to develop their own 5G telecom equipment, such as small-cell base stations, network switches, modems and Internet of things (IoT) devices, a ministry statement said. The open platform would allow Taiwanese manufacturers to tap into the lucrative 5G telecom equipment market, which was previously monopolized by Nokia Oyj, Ericsson AB
CORPORATE SCANDAL: Cathay Life has invested NT$13.3 billion in Bank Mayapada since 2015, but the latest loss of NT$8.8 billion has completely written off its investment Cathay Life Insurance Co (國泰人壽) yesterday said it would recognize an investment loss of NT$8.8 billion (US$298.1 million) in Indonesia’s Bank Mayapada Internasional Tbk PT due to concerns about the lender’s operations amid a corporate scandal. The company said it would revise its earnings result for June, from a net profit of NT$6.52 billion to a net loss of NT$520 million, its first monthly loss over the past 17 months. After booking an investment loss of NT$5.2 billion in Bank Mayapada earlier this year, Cathay Life has so far recognized total investment losses of NT$14 billion in the lender, executive vice president
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported that revenue last month expanded 25 percent annually, but fell 12.8 percent month-on-month to NT$105.96 billion (US$3.59 billion). In the first seven months of this year, the chipmaker’s revenue surged 33.6 percent to NT$727.26 billion, compared with NT$544.46 billion a year earlier. TSMC has said it aims to grow its revenue by more than 20 percent this year. The company has since May 15 stopped taking new orders from Huawei Technologies Co (華為), its second-biggest customer after Apple Inc, due to the US’ restrictions on exports containing US technologies. TSMC has no plans to